Mersana Therapeutics Cash from Financing (TTM) Insights

Mersana Therapeutics Inc (MRSN)

3.485 +0.12 (+3.41%) USD | NASDAQ | May 03, 12:15

Cash from Financing (TTM) Chart

Historical Cash from Financing (TTM) Data

View and export this data back to 2016. Upgrade now.

Date	Value
December 31, 2023	94.68M
September 30, 2023	136.04M
June 30, 2023	146.82M
March 31, 2023	114.17M
December 31, 2022	153.02M
September 30, 2022	140.35M
June 30, 2022	130.18M
March 31, 2022	123.57M
December 31, 2021	63.65M
September 30, 2021	36.52M
June 30, 2021	36.00M
March 31, 2021	230.97M
December 31, 2020	230.41M
September 30, 2020	228.98M
June 30, 2020	229.02M

Date	Value
March 31, 2020	5.41M
December 31, 2019	97.70M
September 30, 2019	97.68M
June 30, 2019	97.90M
March 31, 2019	93.01M
December 31, 2018	1.064M
September 30, 2018	0.874M
June 30, 2018	71.31M
March 31, 2018	69.25M
December 31, 2017	68.60M
September 30, 2017	68.60M
June 30, 2017	-2.078M
March 31, 2017	57.83M
December 31, 2016	58.26M

Cash From Financing Definition

Cash flow from financing is a major line item of the statement of cash flows. This metric tracks the movement of cash flows for the overall financing activities of the company. A few examples of financing activities include common stock issuance, total dividends paid, and net debt issuance.

Read full definition.

Cash from Financing (TTM) Range, Past 5 Years

5.41M

Minimum

Mar 2020

230.97M

Maximum

Mar 2021

125.95M

Average

123.57M

Median

Mar 2022

Cash from Financing (TTM) Benchmarks